Meptazinol

Meptazinol

SCHEMBL542305

Br.CCC1(c2cccc(O)c2)CCCCN(C)C1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1

The experimentally established mechanism targets of Meptazinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 1/20 0.97
ACHE P22303 4/20 0.97
SLC22A1 O15245 1/20 0.97
CHRM2 P08172 1/20 0.97
SLC6A4 P31645 1/20 0.97
CYP2D6 P10635 1/20 0.97
OPRD1 P41143 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meptazinol SCHEMBL25404 0.99 ACHE (1.00) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL11947491 0.99 ACHE (1.00) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL12125416 0.99 ACHE (1.00) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL124401 0.97 ACHE (0.97) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL1651915 0.96 ACHE (0.95) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL3375335 0.92 ACHE (0.86) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL542368 0.92 ACHE (0.86) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL999304 0.92 ACHE (0.86) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL3374823 0.90 ACHE (0.82) ACHESLC22A1CHRM2SLC6A4OPRM1
Meptazinol SCHEMBL11481015 0.90 ACHE (0.82) ACHESLC22A1CHRM2SLC6A4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270847-A1 NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF SHIRE LLC (US) 2012-10-25 US disclosed
EP-2413937-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF Shire LLC (US) 2012-02-08 EP disclosed
EP-1962817-B1 TRANSDERMAL DELIVERY OF A SALT FORM OF MEPTAZINOL SHIRE PHARMACEUTICALS INC (US) 2010-11-17 EP disclosed
US-20100286186-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF SHIRE LLC (US) 2010-11-11 US disclosed
WO-2010112942-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF SHIRE LLC (US) 2010-10-07 WO disclosed
US-20100209483-A1 TRANSDERMAL DELIVERY OF MEPTAZINOL SHIRE PHARMACEUTICALS, INC. 2010-08-19 US disclosed
US-20090186832-A1 AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF SHIRE LLC (US) 2009-07-23 US disclosed
WO-2009092071-A2 AMINO ACID AND PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF SHIRE LLC (US) 2009-07-23 WO disclosed
EP-2061441-A2 TRANSDERMAL DELIVERY OF MEPTAZINOL Shire Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
EP-1962817-A2 TRANSDERMAL DELIVERY OF MEPTAZINOL Shire Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2008022128-A2 TRANSDERMAL DELIVERY OF MEPTAZINOL SHIRE PHARMACEUTICALS, INC. (US) 2008-02-21 WO disclosed
US-20070224253-A1 Transdermal Delivery of Meptazinol SHIRE PHARMACEUTICALS INC. (US) 2007-09-27 US disclosed
WO-2007075883-A9 TRANSDERMAL DELIVERY OF MEPTAZINOL SHIRE PHARMACEUTICALS INC (US) 2007-08-23 WO disclosed
WO-2007075883-A2 TRANSDERMAL DELIVERY OF MEPTAZINOL SHIRE PHARMACEUTICALS, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286186-A1 NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF VIP, OPRL1, OPRK1 OPRM1 4/4885ACHE 492/4885SLC22A1 1134/4885
US-20070224253-A1 Transdermal Delivery of Meptazinol MEP1A, MEP1B, OPRL1 OPRM1 20/4885ACHE 11/4885SLC22A1 1486/4885
US-20100209483-A1 TRANSDERMAL DELIVERY OF MEPTAZINOL MEP1A, OPRL1, MEP1B OPRM1 19/4885ACHE 6/4885SLC22A1 1313/4885
US-20120270847-A1 NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF OPRL1, OPRM1, DNPEP OPRM1 2/4885ACHE 71/4885SLC22A1 1633/4885
US-20090186832-A1 AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF DNPEP, PEPD, PREP OPRM1 42/4885ACHE 62/4885SLC22A1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.